A Phase 1 interventional study of IBI3031 and placebo in Thyroid Eye Disease, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.
Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 22nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 14 of the 27 other live ones, and was the 51st registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–80
Candid Therapeutics · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
Shanghai Changzheng Hospital · Sites in China
Ages 18–70 · Healthy volunteers
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 16 · Phase 4 8
First in 2010; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is close to the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 64 across the 45 interventional studies, 125 across the 10 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 6 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
12 of the studies in Graves Ophthalmopathy with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989918Phase 3Minghui Pharmaceutical (Hangzhou) LtdMHB018A Treatment in Patients With Active Thyroid Eye Disease | 2026-12 |
| NCT07113262Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease | 2026-12-31 |
| NCT07211776Phase 3Zai Lab (Shanghai) Co., Ltd.A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease | 2027-03-14 |
| NCT07720635Phase 3Beijing Kanghong Biological Medicine Co., Ltd.A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease | 2027-04 |
| NCT07720648Phase 3Beijing Kanghong Biological Medicine Co., Ltd.A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease | 2027-05 |
Add all 12 to your calendar (.ics) → With an account.
Among the 55 studies in Graves Ophthalmopathy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.
IBI3031 is an IGF-1R(Insulin-like growth factor 1 receptor)/TSHR(Thyroid-stimulating hormone receptor) bispecific antibody with potential synergistic therapeutic efficacy in TED and modulatory effects on thyroid function. As the first-in-human trial of IBI3031, this study evaluates the safety, tolerability, PK(Pharmacokinetics)/PD(Pharmacodynamics) profiles, immunogenicity, and efficacy of IBI3031 in TED participants. The trial is conducted in two stages: Stage 1- a single-ascending-dose (SAD) study involving single SC or IV administration of IBI3031; Stage 2- a multiple-ascending-dose (MAD) study involving three SC administrations of IBI3031. Approximately 66 TED participants are planned for enrollment: 36 in Stage 1 (allocated at a 3:1 ratio) and 30 in Stage 2 (allocated at a 4:1 ratio).
Key Inclusion Criteria:
Moderate-to-severe active TED:
Key Exclusion Criteria:
Participants to be excluded (Participants meeting any of the following criteria will be regarded as ineligible):
Other medical history and abnormal test results during the screening period that are judged by the investigator to be , may cause the participant to fail to comply with the study protocol or complete the trial, or endanger safety, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive matching placebo to the treatment group.
Drug: placebo
Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.
Drug: IBI3031
Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.
Drug: IBI3031
Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.
Drug: placebo
Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.
Drug: IBI3031
Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.
Drug: placebo
Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.
Drug: IBI3031
Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.
Drug: placebo
Subjects receive matching placebo to the treatment group.
Drug: placebo
Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.(at the same dose level as Arm 2 but via \[different route/method)
Drug: IBI3031
Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.
Drug: IBI3031
Subjects receive matching placebo to the treatment group.
Drug: placebo
Subjects receive matching placebo to the treatment group.
Drug: placebo
Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.
Drug: IBI3031
Subjects receive matching placebo to the treatment group.
Drug: placebo
Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.
Drug: IBI3031
subcutaneous injection or intravenous infusion.
subcutaneous injection or intravenous infusion.
Number, incidence rate, severity, and association with the study drug of Adverse Events (AEs)
The number, incidence rate, severity, and association with the study drug of all AEs occurring throughout the trial will be summarized.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Number, incidence rate, severity, and association with the study drug of Treatment-Emergent Adverse Events (TEAEs)
The number, incidence rate, severity, and association with the study drug of all TEAEs after study drug administration will be summarized.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Number, incidence rate, severity, and association with the study drug of Serious Adverse Events (SAEs)
The number, incidence rate, severity, and association with the study drug of all SAEs will be summarized.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Change in systolic and diastolic blood pressure after dosing in each dose group(Unit of Measure: mmHg)
Systolic and diastolic blood pressure will be measured and recorded at each specified time point
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Number of participants with clinically significant abnormal findings in complete physical examination(Unit of Measure: participants)
A complete physical examination will be performed at each specified time point, including assessment of general appearance, respiratory system, cardiovascular system, abdomen, skin, head and neck (including ears, nose, and throat), lymph nodes, thyroid gland, musculoskeletal system (including spine and extremities), and neurological system. Any finding that is new or worsened from baseline and deemed clinically significant by the investigator will be
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Changes in hematology laboratory parameters before and after dosing in each dose group
Changes in hematology parameters including white blood cell count, red blood cell count, hemoglobin, and platelet count will be recorded.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Changes in blood chemistry laboratory parameters before and after dosing in each dose group
Changes in blood chemistry parameters including liver and renal function, electrolytes, and blood glucose will be recorded.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Changes in urinalysis laboratory parameters before and after dosing in each dose group
Changes in urinalysis parameters including urine protein, urine occult blood, and urine leukocytes will be recorded.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Changes in thyroid function laboratory parameters before and after dosing in each dose group
Changes in thyroid function parameters including thyroid-stimulating hormone, free triiodothyronine, and free thyroxine will be recorded.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Number of subjects with abnormal ECG changes before and after administration in each dose group
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Changes in pure-tone audiometry results before and after dosing in each dose group
Changes in hearing thresholds at each frequency (500 Hz, 1000 Hz, 2000 Hz, 4000 Hz) will be recorded.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Change in heart rate after dosing in each dose group (Unit of Measure: beats per minute)
Heart rate will be measured and recorded at each specified time point.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Change in body temperature after dosing in each dose group(Unit of Measure: °C)
Body temperature will be measured and recorded at each specified time point.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Change in respiratory rate after dosing in each dose group( Unit of Measure: breaths per minute)
Respiratory rate will be measured and recorded at each specified time point.
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Area Under the Curve (AUC) of the serum concentration-time profile
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Maximum Concentration (Cmax) of the drug in serum
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Clearance (CL)
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Volume of Distribution (Vd)
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Elimination Half-life (t1/2)
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Production of anti-drug antibodies (ADAs) and/or neutralizing antibodies (NAbs) in serum
Time frame: up to Day 85 for SAD;up to Day 337 for MAD
Proportion of participants with proptosis response
Defined as a ≥2 mm reduction in proptosis in the study eye from baseline, without a ≥2 mm increase in proptosis in the fellow eye
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
Proportion of participants with overall response
Defined as a ≥2-point reduction in the Clinical Activity Score (CAS) from baseline in the study eye, a ≥2 mm reduction in proptosis in the study eye from baseline, and no worsening in the fellow eye (worsening defined as a ≥2-point increase in CAS or a ≥2 mm increase in proptosis)
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
Number of subjects with changes in proptosis from baseline after dosing
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
Proportion of participants with CAS = 0 or 1
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
CAS change from baseline
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
Proportion of participants with diplopia response
Defined as a ≥1-point reduction in diplopia
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
Total score of the Graves' Ophthalmopathy Quality of Life
The effect of thyroid eye disease on social activities and appearance during the past 1 week.
Time frame: Day 8, Day 29, Day 57, and Day 85 for single ascending dose (SAD) stage; Week 5, Week 9, Week 13, Week 17, Week 21, Week 29, Week 37, and Week 49 for multiple ascending dose (MAD) stage
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovent Biologics (Suzhou) Co. Ltd. →